Answer
Ivosidenib targets mutated IDH1 and is licensed only when an appropriate test confirms an IDH1 R132 mutation.
Sources for this answer
- Tibsovo — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.